Jefferies Maintains Buy on Boston Scientific, Lowers Price Target to $67

Benzinga Newsdesk www.benzinga.com Negative 60.2%

Neg 60.2% Neu 0% Pos 0%

Jefferies analyst Matthew Taylor maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $100 to $67.